CLAIMS

1. A solid form of the compound of formula (Id)



(Id)

wherein said solid form is selected from:

a) a form of the zwitterion of compound (Id);

b) an alkali metal salt of the compound of formula (Id); and

c) a halogen salt of the compound of formula (Id).

2. The solid form according to claim 1, wherein said solid form is a crystalline form.

3. The solid form according to any one of claims 1 and 2, wherein said solid form is selected from the group consisting of the dihydrate of the zwitterion of compound (Id), the heptahydrate of the zwitterion of compound (Id) and the potassium salt of the compound (Id).

4. The solid form according to any one of claims 1-3, wherein said solid form is the dihydrate of the zwitterion of compound (Id) or the potassium salt of the compound (Id).

5. The solid form according to any one of claims 1-4, wherein said solid form is the dihydrate characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks as listed for the dihydrate in Table 2, group (a).

6. The solid form according to any one of claims 1-5, wherein said solid form is the dihydrate characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ-angles ± 0.2° 2θ :10.4, 11.6, 12.3 and 13.1 and 13.6°.

7. The solid form according to any one of claims 6, wherein said x-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of peaks at the following 2θ-angles ± 0.2° 2θ: 14.3, 15.6, 16.0, 16.8 and 18.5°.

8. The solid form according to any one of claims 2-7, wherein said solid form is a crystal form characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) essentially as depicted in Figure 8a.

9. The solid form according to any one of claims 1-8, said solid form exhibiting a weight loss of about 7.6% w/w compared to the initial weight when heated from about 30°C to about 150°C (heating rate 10°C/min), such as measured using thermogravimetric analysis.

10. The solid form according to any one of claims 1-2, wherein said solid form is the potassium salt characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks as listed for the potassium salt in Table 2, group (a).

11. The solid form according to claim 10, wherein said potassium salt has a crystal form characterized by an XRPD obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ-angles ± 0.2° 2θ: 3.0, 9.0, 12.6, 13.6, and 15.0°.

12. The solid form according to claim 11, wherein said x-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of peaks at the following 2θ-angles ± 0.2° 2θ: 17.1, 18.0, 18.4, 18.8 and 19.4°.

13. The solid form according to any one of claims 1-3 and 11-12, said form exhibiting a weight loss of less than about 1% w/w compared to the initial weight when heated from about 20°C to about 150°C (heating rate 10°C/min), such as measured using thermogravimetric analysis.

14. The solid form of the compound of formula (Id) according to any of claims 1-13, for use as a medicament.

15. A pharmaceutical composition comprising a therapeutically effective amount of the solid form of the compound of formula (Id) according to any one of claims 1-13, and one or more pharmaceutically acceptable excipients.

16. A solid form of the compound of formula (Id) according to any one of claims 1-13, for use in the treatment of a neurodegenerative disease or disorder such as Parkinson's Disease, Huntington's disease, Restless leg syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.

17. Use of solid form of the compound of formula (Id) according to any one of claims 1-13, in the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder such as Parkinson's Disease, Huntington's disease, Restless leg syndrome or Alzheimer's disease; or for the treatment of a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.